title: Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome.
abstract: BACKGROUND
  ACTH-independent macronodular adrenal hyperplasia (AIMAH) is a rare and heterogeneous condition characterized by abnormal steroid production. Cortisol secretion can be regulated by aberrant hormone receptors.
  
  
  OBJECTIVE
  A large series of patients with AIMAH were evaluated to provide information on the prevalence and profile of aberrant regulations, in relation with the functional status.
  
  
  METHODS
  Thirty-two consecutive patients with AIMAH were prospectively studied: 10 had a Cushing's syndrome (CS), and 22 had a subclinical CS (SCS).
  
  
  METHODS
  A baseline endocrine evaluation was followed by an in vivo protocol in search of aberrant cortisol responses (seven provocative tests). An acute inhibition test with the somatostatin analog octreotide was also performed.
  
  
  RESULTS
  At least one aberrant cortisol response was identified in 28 of 32 (87%) patients. The overall prevalence of aberrant responses was independent of the functional status. Responses to the upright posture and to metoclopramide were frequently observed (67 and 56% respectively). A glucagon response was frequently observed in the SCS group (58%). A cortisol inhibition by octreotide was specifically found in the three CS patients who positively responded to the mixed meal, and was observed also in 12 of 13 (92%) patients with SCS.
  
  
  CONCLUSIONS
  Cortisol responses indicative of aberrant receptor expression were highly prevalent in AIMAH. Thorough phenotyping of AIMAH may help uncover the underlying pathophysiology.
authors.affiliation: Department of Endocrinology, Metabolism and Cancer, Institut National de la Santé et de la Recherche Médicale Unité 567, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Institut Cochin, 75014 Paris, France.
authors.forename: Rossella
authors.initials: R
authors.lastname: Libé
authors.forename: Joël
authors.initials: J
authors.lastname: Coste
authors.forename: Laurence
authors.initials: L
authors.lastname: Guignat
authors.forename: Frédérique
authors.initials: F
authors.lastname: Tissier
authors.forename: Hervé
authors.initials: H
authors.lastname: Lefebvre
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Barrande
authors.forename: Christiane
authors.initials: C
authors.lastname: Ajzenberg
authors.forename: Igor
authors.initials: I
authors.lastname: Tauveron
authors.forename: Eric
authors.initials: E
authors.lastname: Clauser
authors.forename: Bertrand
authors.initials: B
authors.lastname: Dousset
authors.forename: Xavier
authors.initials: X
authors.lastname: Bertagna
authors.forename: Jérôme
authors.initials: J
authors.lastname: Bertherat
authors.forename: Lionel
authors.initials: L
authors.lastname: Groussin
mesh_terms: D000307:Adrenal Gland Diseases / Q000097:blood* / Q000652:urine*; D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000328:Adult; D003480:Cushing Syndrome / Q000097:blood* / Q000652:urine*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood* / Q000652:urine*; D006965:Hyperplasia / Q000097:blood* / Q000652:urine*; D008297:Male; D011446:Prospective Studies; D013004:Somatostatin / Q000031:analogs & derivatives / Q000494:pharmacology; D055815:Young Adult
chemical_list: D013004:Somatostatin; D006854:Hydrocortisone